CURATE.AI Optimized Modulation for Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Clinical trial applying CURATE.AI, a Phenotypic Precision Medicine (PPM) platform, to
Bortezomib, Thalidomide and Cyclophosphamide dosing in multiple myeloma patients to show
improvement in response.